Albumin-bound Paclitaxel Plus S-1 Versus SOX as First-line Treatment in Advanced or Recurrent Gastric Adenocarcinoma
Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
It is a trial to compare the efficacy and safety of Albumin-bound Paclitaxel plus S-1 versus
Oxaliplatin plus S-1 (SOX) as first-line treatment in advanced or recurrent gastric
adenocarcinoma.